- Home
- / Shanghai Hile Bio-Technology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Shanghai Hile Bio-Technology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
¥267.1 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 251.9M | 275.5M | 256.1M | 342.7M | 290.8M | 228.2M | 267.1M |
| Cost of goods sold | 112.4M | 148.7M | 137.8M | 153.6M | 123.1M | 117.0M | 107.9M |
| Gross profit | 139.6M | 126.7M | 119.1M | 190.2M | 173.6M | 120.6M | 159.3M |
| Gross profit margin, % | 55.4% | 46.0% | 46.5% | 55.5% | 59.7% | 52.8% | 59.6% |
| Operating expense total | 89.0M | 79.1M | 84.0M | 109.0M | 123.6M | 100.4M | 78.3M |
| Depreciation and amortization | 62.1M | 57.7M | 66.1M | 60.2M | 41.2M | 35.9M | 70.9M |
| EBITDA | 55.2M | 47.2M | 37.4M | 91.9M | 58.0M | 31.7M | 92.6M |
| EBITDA margin, % | 21.9% | 17.1% | 14.6% | 26.8% | 19.9% | 13.9% | 34.7% |
| EBIT | (20.8M) | (7.3M) | (30.5M) | 41.6M | 125.2M | (14.4M) | 42.7M |
| EBIT margin, % | -8.3% | -2.7% | -11.9% | 12.1% | 43.1% | -6.3% | 16.0% |
| Interest income | 527.0K | 66.0K | 145.0K | 175.0K | 2.2M | 2.7M | 2.2M |
| Interest expense | 14.9M | 18.2M | 17.7M | 12.4M | 10.3M | 5.4M | 5.5M |
| Pre tax profit | (1.2M) | 6.8M | (23.3M) | 57.1M | 131.2M | 56.0M | 208.1M |
| Income tax expense | 12.5M | 33.2M | 8.8M | 11.5M | 20.5M | 6.0M | 26.5M |
| Net Income | (13.7M) | (26.4M) | (32.2M) | 45.7M | 110.7M | 50.0M | 181.6M |